Cognitive complaints after breast cancer treatments: patient report and objective evidence.

jnci.oxfordjournals.org 6. Greco FA, Spigel DR, Yardley DA, Erlander MG, Ma XJ, Hainsworth JD. Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction. Oncologist. 2010;15:500–506. 7. Greco FA, Oien K, Erlander M, et al. Cancer of unknown primary: progress in the search for improved and rapid diagnosis leading toward superior patient outcomes. Ann Oncol. 2012;23(2):298–304. 8. Monzon FA, Koen TJ. Diagnosis of metastatic neoplasms: molecular approaches for identification of tissue of origin. Arch Pathol Lab Med. 2010;134(2):216–224. 9. Bender RA, Erlander MG. Molecular classification of unknown primary cancer. Semin Oncol. 2009;36(1):38–43. 10. Talantov D, Baden J, Jatkoe T, et al. A quantitative reverse transcriptasepolymerase chain reaction assay to identify metastatic carcinoma tissue of origin. J Mol Diagn. 2006;8(3):320–329. 11. Varadhachary GR. Carcinoma of unknown primary: focused evaluation. J Natl Compr Canc Netw. 2011;9(12):1406–1412. 12. Greco FA, Lennington WJ, Spigel DR, Hainsworth JD. Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology. J Natl Cancer Inst. 2013;105(11):782–790. 13. Hainsworth JD, Rubin MS, Spigel DR, et al. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon Research Institute. J Natl Cancer Inst. 2013;31(2):217–223.